AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes

Co-Host: Yair Lotan, MD At the conclusion of these activities, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual p...

18 Dec 201937min

Co-Host: Brian M. Shuch, MD At the conclusion of these activities, participants will be able to: 1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological age...

11 Dec 201927min

Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify b...

4 Dec 201932min

Co-Host: Alicia K. Morgans, MD, MPH At the conclusion of these activities, participants will be able to: 1. Recognize cardiovascular comorbidities and describe their management in the context of pros...

27 Nov 201928min

Co-Host: Brian Shuch, MD At the conclusion of these activities, participants will be able to: 1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and opt...

18 Nov 201925min

Co-Host: Vitaly Margulis, MD At the conclusion of these activities, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and bene...

13 Nov 201924min

The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology. This...

5 Nov 201950min

Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both compl...

31 Okt 201935min